✦ LIBER ✦

+331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer

✍ Scribed by Joanne Kotsopoulos; Shelley S. Tworoger; Immaculata DeVivo; Susan E. Hankinson; David J. Hunter; Walter C. Willett; Wendy Y. Chen

Publisher: John Wiley and Sons
Year: 2009
Tongue: French
Weight: 103 KB
Volume: 125
Category: Article
ISSN: 0020-7136
DOI: 10.1002/ijc.24477

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

A functional promoter polymorphism in the progesterone receptor (PR) gene previously has been associated with an increased risk of postmenopausal breast cancer. Whether the relationship between genetic variation in PR and risk of breast cancer is modified by postmenopausal hormone (PMH) use is unknown. Thus, we conducted a case–control study nested within the prospective Nurses' Health Study to evaluate if the risk of breast cancer associated with having the +331 A risk allele was modified by PMH use. Genotyping of this SNP was available for 1,664 postmenopausal breast cancer cases and 2,391 controls. Logistic regression was used to estimate the odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer. Women who were carriers of 1 or both variant A alleles had a 31% increased risk of developing breast cancer (95% CI 1.04–1.65). PMH use significantly modified the association between the +331G/A polymorphism and risk (p‐interaction <0.05). Among never users of PMH, women who were variant carriers had a significantly increased risk of breast cancer compared to those with the wild‐type genotype (OR = 2.57; 95% CI 1.64–4.02). The +331G/A polymorphism was not associated with breast cancer risk among past (OR = 1.23; 95% CI 0.77–1.97) or current (OR = 1.14; 95% CI 0.84–1.56) PMH users. The data from this large prospective study provide evidence for a 2‐fold increased risk of developing postmenopausal breast cancer among never users of PMH with the +331G/A SNP. This finding adds to the evidence that the PR has an important etiologic role in breast cancer and should be evaluated in future studies. © 2009 UICC

📜 SIMILAR VOLUMES

Polymorphisms in genes of the steroid re

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy

✍ The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone The 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 183 KB 👁 1 views

## Abstract Menopausal hormone therapy (HT) is associated with increased breast cancer risk among postmenopausal women. Nuclear receptors are involved in steroid hormone‐ and xenobiotic‐mediated signal transduction playing a crucial role in regulating gene expression. Therefore, variations within t

Gene regulation profile reveals consiste

Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptor

✍ Joyce C.L. Leo; Suk Mei Wang; Chun Hua Guo; Swee Eng Aw; Yi Zhao; Jin Ming Li; K 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 137 KB

Absence of estrogen receptor (ER) and progesterone receptor (PR) is the hallmark of most hormone-independent breast cancers. Previous studies demonstrated that reactivation of PR expression in hormone-independent MDA-MB-231 breast cancer cells enabled progesterone to suppress cell growth both in vit

Association of the progesterone receptor

Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population

✍ Wang-Hong Xu; Ji-rong Long; Wei Zheng; Zhi-xian Ruan; Qiuyin Cai; Jia-rong Cheng 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

## Abstract ## BACKGROUND: Single nucleotide polymorphisms (SNPs) in the progesterone receptor (__PGR__) gene have been associated with the risk of endometrial cancer. However, to the authors' knowledge, no study to date has systematically evaluated the role of the __PGR__ gene in endometrial carc

Novel alternatively spliced variant with

Novel alternatively spliced variant with a deletion of 52 BP in exon 6 of the progesterone receptor gene is observed frequently in breast cancer tissues

✍ Hisashi Hisatomi; Norio Kohno; Kazuyuki Wakita; Kumi Nagao; Hiroyuki Hirata; Kaz 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 301 KB 👁 1 views

## Abstract The human progesterone receptor (PR) is a ligand‐activated nuclear transcription factor that mediates progesterone action in target tissues. We found a novel alternatively spliced variant (ASV) of the PR mRNA in breast cancer tissues. The deleted transcript was characterized by an out‐o

Dietary fiber intake and risk of postmen

Dietary fiber intake and risk of postmenopausal breast cancer defined by estrogen and progesterone receptor status—A prospective cohort study among Swedish women

✍ Reiko Suzuki; Tove Rylander-Rudqvist; Weimin Ye; Shigehira Saji; Herman Adlercre 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 131 KB 👁 1 views

## Abstract There is few data on the association between dietary fiber intake and estrogen receptor (ER)/progesterone receptor (PR)‐defined breast cancer risk. We evaluated the association between dietary fiber and ER/PR‐defined breast cancer risk stratified by postmenopausal hormone use, alcohol i

The impact of tumor progesterone recepto

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer : A decision analysis

✍ Rinaa S. Punglia; Karen M. Kuntz; Eric P. Winer; Jane C. Weeks; Harold J. Burste 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 1 views